What you see is not always what you get: Raising the bar on clinical trial methodology in ulcerative colitis

Gastroenterology

Volumn 145, Issue 1, 2013, Pages 45-47

  Rubin, David T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PLACEBO;

CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENDOSCOPY; EQUIPOISE; GOOD CLINICAL PRACTICE; HUMAN; INTENTION TO TREAT ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REMISSION; SIGMOIDOSCOPY; STUDY DESIGN; ULCERATIVE COLITIS;

EID: 84879485782     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.05.027     Document Type: Editorial

References (5)

1. L.R. Sutherland, F. Martin, and S. Greer 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis Gastroenterology 92 1987 1894 1898
2. B.G. Feagan, W.J. Sandborn, and G. D'Haens The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis Gastroenterology 145 2013 149 157
3. M.A. Kamm, W.J. Sandborn, and M. Gassull Once-daily, high-concentration MMX mesalamine in active ulcerative colitis Gastroenterology 132 2007 66 75
4. G.R. Lichtenstein, M.A. Kamm, and P. Boddu Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis Clin Gastroenterol Hepatol 5 2007 95 102
5. S.P. Travis, D. Schnell, and P. Krzeski Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) Gut 61 2012 535 542